Vaxcyte, Inc. Q4 FY2023 earnings call

2023 was a significant year for Vaxcyte with progress in PCV programs. VAX-24 completed adult Phase 2 with positive data, confirming strong immune responses compared to Prevnar 20. VAX-31 initiated adult Phase 1/2 study, with enrollment completed in early 2024. There was regulatory progress with the FDA on VAX-24 Phase 3 clinical design. The company strengthened its balance sheet with substantial financing, allowing funding of key milestones. Manufacturing investments were made in a dedicated suite at Lonza to support global commercialization. Pipeline updates included earlier-stage candidates like VAX-A1, VAX-PG, and VAX-GI.

No detailed financial performance data for product segments provided in the transcript.

Expect topline data from VAX-31 adult Phase 1/2 study in the third quarter of 2024. VAX-24 infant Phase 2 study primary series data is expected by the end of Q1 2025, with booster data by end of 2025. Plan to initiate Phase 3 studies for adult PCV programs in 2024-2026, with BLA submission following completion of the last study. Cash position provides funding for milestones over the next few years, including clinical trial readouts and manufacturing buildout.

Regulatory uncertainties in clinical trial approvals and BLA submissions. Potential clinical trial outcomes not meeting expectations. Market competition and changing ACIP recommendations could impact program progress.

Q: Framing success for VAX-31 vs VAX-24 and exploring protein carrier reduction in VAX-31 A: Grant Pickering discussed non-inferiority endpoints and potential adjustments in protein carrier. He mentioned looking at endpoints like OPA geometric mean ratios and fourfold rise in titers, and noted potential adjustments in protein carrier if needed.

Q: Leveraging VAX-24 end of Phase 2 meeting for VAX-31 and CMC aspects A: Jim Wassil stated they plan to leverage similar study designs from VAX-24 for VAX-31, and use similar manufacturing processes and CMC considerations as with VAX-24.

Q: ACIP recommendations and prime boost opportunity in adults A: Grant and Jim discussed ACIP potential on Merck's V116 and the prime boost opportunity in adults, with talk of potential universal vaccination from age 50 down and the importance of including at-risk populations in studies.

Q: Global manufacturing capacity and infant program choices A: Grant Pickering talked about manufacturing buildout as key to competitive advantage and mentioned considering both VAX-24 and VAX-31 for the infant program based on data readouts.

Q: Preclinical programs, including Group A Strep A: Jim Wassil discussed the Group A Strep program, highlighting its importance due to high disease burden and economic impact, and noted minimal competitive activity in this space